Ifinatamab deruxtecan

Ifinatamab deruxtecan (I-DXd) is an investigational potential first-in-class B7-H3 directed ADC. B7 homolog 3 (B7-H3), a transmembrane immunoregulatory protein, is overexpressed in several tumor types, including small cell lung cancer (SCLC), where about two-thirds of patients have moderate-to-high expression of B7-H3, which has been associated with disease progression and lower survival. Ifinatamab deruxtecan is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Ifinatamab deruxtecan was granted orphan drug designation by the U.S. Food and Drug Administration in April 2023 and by the European Commission in February 2024 for the treatment of SCLC. It has average molecular weight of 153KDa. The DAR is n = ~4. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Ifinatamab (Anti-B7-H3 Monoclonal Antibody)
ADC cytotoxin (drug)	Dxd
Immunogen	B7 homolog 3 (B7-H3)
DAR (Drug to Antibody Ratio)	~4
Purity	98%
Molecular Weight	153kDa
Protein Concentration	10mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	PBS buffer pH7.4